| 1. |
Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente
JR et al. Pharmacology and neurochemistry of nefazodone, a novel antidepressant
drug. J Clin Psychiatry 1995;56 Supl 6:3-11.
|
|
| 2. |
Feighner JP, Bennett ME, Roberts DL et al. A double-blind trial of
nefazodone versus placebo in depressed inpatients. New Research Program and
Abstracts. APA Annual Meeting. New York: APA; 1996.
|
| 3. |
Marcus RN, Mendels J. Nefazodone in the treatment of severe, melancholic,
and recurrent depression. J Clin Psychiatry 1996; 57 Supl 2:19-23.
|
| 4. |
Rickels K, Schweizer E, Clary C, Fox I, Weise C. Nefazodone and imipramine
in major depression: a placebo-controlled trial. Br J Psychiatry 1994;164:802-5.
|
| 5. |
Fontaine R, Ontiveros A, Eliere R, Kensler TT, Roberts DL, Kaplita S et al.
A double-blind comparison of nefazodone, imipramine, and placebo in major
depression. J Clin Psychiatry1994;55:234-41.
|
| 6. |
Mendels J, Reimherr F, Marcus RN, Roberts DL, Francis RJ, Anton SF. A
double-blind, placebo-controlled trial of two dose ranges of nefazodone in the
treatment of depressed outpatients. J Clin Psychiatry 1995;56 Supl 6:30-6.
|
| 7. |
Cohn CK, Robinson DS, Roberts DL, Schwiderski UE, O'Brien K, Ieni JR.
Responders to antidepressant drug treatment: A study comparing nefazodone,
imipramine, and placebo in patients with major depression, J Clin Psychiatry
1996;57 Supl 2:15-8.
|
| 8. |
Baldwin DS, Hawley CJ, Abed RT, Maragakis DP, Cox J, Buckingham SA et al. A
multicenter double-blind comparison of nefazodone and paroxetine in the
treatment of outpatients with moderate-to-severe depression. J Clin Psychiatry
1996;57 Supl 2:46-52.
|
| 9. |
Feiger E, Kiev A, Shrivastava RK, Wisselink PG, Wilcox CS. Nefazodone
versus sertraline in outpatients with major depression: focus on efficacy,
tolerability and effects on sexual function and satisfaction. J Clin Psychiatry
1996;57 Supl 2:53-62.
|
| 10. |
Rioux P, Kibleur Y, Frachon O et al. A double-blind comparison of
nefazodone and fluoxetine in depressed patients. New Research Program and
Abstracts. APA Annual Meeting. New York: APA; 1996. |
| 11. |
Feiger AD, Bielski RD, Bremner JD et al. Efficacy of nefazodone in
continuation treatment of depression. New Research Program and Abstracts. APA
Annual Meeting. New York: APA; 1996. |
| 12. |
Anton SF, Robinson DS, Roberts D, Kensler TT, English PA, Archibald DG.
Long-term treatment of depression with nefazodone. Psychopharmacol Bull
1994;30:165-9.
|
| 13. |
Eison AS, Eison MS, Torrente JR, Wright RN, Yocca FD. Nefazodone:
preclinical pharmacology of a new antidepressant. Psychopharmacol Bul
1990;26:311-5.
|
| 14. |
Fontaine R. Novel serotonergic mechanisms and clinical experience with
nefazodone. Clin Neuropharmacol 1993;16 Supl 3:S45-S50.
|
| 15. |
Fawcett J, Marcus RN, Anton SF, O'Brien K, Schwiderski U. Response of
anxiety and agitation symptoms during nefazodone treatment of major depression.
J Clin Psychiatry 1995;56 Supl 6:37-42.
|
| 16. |
Nutt D. Early action of nefazodone in anxiety associated with depression. J
Psychopharmacol 1996;10 Supl 1:18-21.
|
| 17. |
Zajecka JM. The effect of nefazodone on comorbid anxiety symptoms
associated with depression: Experience in family practice and psychiatric
outpatient settings. J Clin Psychiatry 1996;57 Supl 2:10-4.
|
| 18. |
Sharpley AL, Walsh AE, Cowen PJ. Nefazodone-a novel antidepressant-may
increase REM sleep. Biol Psychiatry 1992;31:1070-3.
|
| 19. |
Ware JC, Rose FV, McBrayer RH. The acute effects of nefazodone, trazodone
and buspirone on sleep and sleep-related penile tumescence in normal subjects.
Sleep 1994;17:544-50.
|
| 20. |
Armitage R, Rush AJ, Trivedi M, Cain J, Roffwarg HP. The effects of
nefazodone on sleep architecture in depression. Neuropsychopharmacology
1994;10:123-7.
|
| 21. |
Sharpley AL, Walsh AES, Cowen PJ. Effect of nefazodone and lithium on sleep
architecture in healthy men. J Psychoparmacol 1996;10:26-9.
|
| 22. |
Rush AJ, Gillin C, Armitage R et al. Comparative effects of nefazodone and
fluoxetine on sleep in outpatients with major depressive disorders. New Research
Program and Abstracts. APA Annual Meeting. New York: APA; 1996. |
| 23. |
Sharpley AL, Williamson DJ, Attenburrow MEJ, Pearson G, Sargent P, Cowen
PJ. The effects of paroxetine and nefazodone on sleep: a placebo controlled
trial. Psychopharmacology 1996;126:50-4.
|
| 24. |
Freeman EW, Rickels K, Sondheimer SJ, Denis A, Pfeifer S, Weil S.
Nefazodone in the treatment of premenstrual syndrome: A preliminary study. J
Clin Psychopharmacol 1994;14:180-5.
|
| 25. |
Van Ameringen MA, Mancini CL, Oakman J et al. Nefazodone in the treatment
of social fobia. New research. Program and abstracts. APA Annual Meeting, 197.
San Diego: APA; 1997.
|
| 26. |
De Martinis NA, Schweizer E, Rickels K. An open-label trial of nefazodone
in high comorbidity panic disorders. J Clin Psychiatry 1996;57:245-8.
|
| 27. |
Mellman TA, David D, Barza L. Pilot study of nefazodone for chronic PTSD
and related sleep disturbance. New research. Program and abstracts. APA Annual
Meeting, 202. San Diego: APA; 1997.
|
| 28. |
Worthington III JJ, Pollack MH. Treatment of dysphoric mania with
nefazodone. Am J Psychiatry 1996;153:732-3.
|
| 29. |
Ketter TA, Callahan AM, Post RM. Nefazodone relief of alprazolam interdose
dysphoria: a potential therapeutic benefit of 3A3/4 inhibition. J Clin
Psychiatry 1996;57:307.
|
| 30. |
Robinson DS, Roberts DL, Smith JM, Stringfellow JC, Kaplita SB, Seminara
JA. The safety profile of nefazodone. J Clin Psychiatry 1996;57 Supl 2:31-8.
|
| 31. |
Breuel HP, DeLeenher I, Coninx L et al. Comparison of the cardiovascular
effects of nefazodone, imipramine and placebo in healthy elderly volunteers. Eur
Neuropsychopharmacol 1993;3:423.
|
| 32. |
Prekorn SH. Comparison of the tolerability of bupropion, fluoxetine,
imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin
Psychiatry 1995;56 Supl 6:12-21.
|
| 33. |
De Vane CL. Comparative safety and tolerability of selective serotonin
reuptake inhibitors. Hum Psychopharmacol 1995;2:S185-S193.
|
| 34. |
Ferguson JM, Shrivastava RK, Stahl SM et al. Effcts of double-blind
treatment with nefazodone or sertraline on re-emergence of sexual dysfunction in
depressed patients. New Research Program and Abstract. APA Annual Meeting. New
York: APA; 1996.
|
| 35. |
Settle EC Jr. Antidepressant side effects issues and options. J Clin
Psychiatry Monograph 1992;10:48-61.
|
| 36. |
Stahl SM, Frakes DC. Nefazodone and the serotonin receptor modulators: a
new member of a unique class of antidepressant agents. Int Rev Psychiatry
1995;:29-39.
|
| 37. |
Goldberg RJ. Nefazodone and venlafaxine: two new agents for the treatment
of depression. J Family Pract 1995;41:591-4.
|
| 38. |
Mayol RF, Cole CA, Luke GM, Colson KL, Kerns EH. Characterization of the
metabolites of the antidepressant drug nefazodone in human urine and plasma.
Drug Metab Disposit 1994;22(2):304-11.
|
| 39. |
Dopheide JA, Stimmel GL, Yi DD. Focus on nefazodone: a serotonergic drug
for major depression. Hosp Formul 1995;30:205-12.
|
| 40. |
Lane RM. Pharmacokinetic drug interaction potential of selective serotonin
reuptake inhibitors. Int Clin Psychopharmacol 1966;11 Supl 5:31-61.
|
| 41. |
Barbhaiya RH, Shukla UA, Kroboth PD, Greene DS. Coadministration of
nefazodone and benzodiazepines: II. A pharmacokinetic interactions study with
triazolam. J Clin Psychopharmacol 1995;15:320-6.
|
| 42. |
Barbhaiya RH, Shukla UA, Greene DS, Breul HP, Midha KK. Investigation of
pharmacokinetic and pharmacodynamic interactions after coadministration of
nefazodone and haloperidol. J Clin Psychopharmacol 1996;16(1):26-34.
|
| 43. |
Mungall D, Docktor W. Pharmacokinetics: an introduction. En: Mungall DR,
editor. Applied Clinical Pharmacokinetics. New York: Raven Press; 1983.
|
| 44. |
Physician`s Desk Reference. 49 ed. Montvale, NJ: Medical Economics Data
Production company, 2109-2111; 2390-2393, 1995.
|
| 45. |
Green DS, Salazar DE, Dockens RC, Kroboth P, Barbhaiya RH. Coadministration
of nefazodone and benzodiazepines: IV. A pharmacokinetic interaction study with
lorazepam. J Clin Psychopharmacol 1995;15(6):409-16.
|
| 46. |
Dockens RC, Rapoport D, Roberts D, Greene DS, Barbhaiya RH. Lack of an
effect of nefazodone on the pharmacokinetics and pharmacodynamics of teophylline
during concurrent administration in patients with chronic obstructive pulmonary
disease. Br J Clin Pharmacol 1995;40(6):598-601.
|
| 47. |
Salazar DE, Dockens RC, Milbrath RL, Raymond RH, Fulmor IE, Chaikin PC.
Pharmacokinetic and pharmacodynamic evaluation of warfarin and nefazodone
coadministration in healthy subjects. J Clin Pharmacol 1995;35(7):730-8.
|
| 48. |
Robinson DS, Marcus RN, Archibald DG, Hardy SA. Therapeutic dose range of
nefazodone in the treatment of major depression. J Clin Psychiatry 1996;57 Supl
2:6-9.
|
| 49. |
Markovitz PJ. An open trial of once versus twice daily nefazodone. New
Research. Program and abstracts. APA Annual Meeting, 128. San Diego: APA; 1997.
|
| 50. |
Preskorn SH, Magnus RD, Markovitz PJ et al. Once-daily dosing of nefazodone
for the treatment of depression in patients previously stabilized on twice-daily
dosing. New research. Program and abstracts. APA Annual Meeting, 128. San Diego:
APA; 1997.
|